Hypersensitivity to atorvastatin calcium or to any components of Avamax.
Active liver disease or unexplained persistent elevations of serum transaminases and diseases of skeletal muscles.
Use in pregnancy & lactation: Atorvastatin is contraindicated during pregnancy and breastfeeding. Cholesterol and other substances, which are formed during its biosynthesis, are essential for fetus development (also formation of steroids and cell membranes). 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors reduce cholesterol synthesis and possibly also synthesis of other biologically active substances which are cholesterol derivatives; its administration in pregnancy may therefore induce harmful effects in fetus. Usage of HMG-CoA reductase inhibitors is thus contraindicated in pregnancy and breastfeeding. Atorvastatin may be administered to women of childbearing potential only when such patients are highly unlikely to conceive and have been informed of the potential harmful effects of Avamax. If the woman becomes pregnant while taking atorvastatin, it should be discontinued and the patient advised again as to the potential hazards to the fetus.
Because of the potential for adverse reactions in nursing infants, women taking atorvastatin should not breastfeed.